

EXACT SCIENCES' COLOGUARD WINS PRESTIGIOUS PRIX GALIEN AWARD FOR BEST MEDICAL TECHNOLOGY PRODUCT

By [Exact Sciences](#) / October 28, 2016



MADISON, Wis., Oct. 28, 2016 /PRNewswire/ — [Exact Sciences Corp.](#) (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition.

"It's an extraordinary honor for Cologuard and the Exact Sciences team to be recognized in such a distinguished forum," said Graham Lidgard, Ph.D., chief science officer of Exact Sciences. "This Prix Galien award highlights not only the breakthrough science behind

cancer. We are humbled and thankful to be counted among the companies honored by the Galien Foundation."

Awarded in more than a dozen countries, the Prix Galien awards recognize the best in biomedical research and development. Nominees for the Prix Galien USA awards represent the most innovative biopharma and medical technologies addressing public health priorities and are evaluated by a prestigious committee comprised of nine renowned leaders from the biomedical industry and academia, including four Nobel Laureates.

The awards were presented at the Prix Galien USA Awards Ceremony, which took place on Oct. 27 at the American Museum of Natural History in New York.



The Exact Sciences and Mayo Clinics team at the Prix Galien USA Awards Ceremony Oct. 27 in New York

to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

About Cologuard

Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the *New England Journal of Medicine* in March 2014. Cologuard is included in the recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society's (2014) colorectal cancer screening guidelines. Stool DNA is included in the combined screening guidelines of the American Cancer Society/U.S. Multi-Society Task Force/American College of Radiology (2008), the American College of Gastroenterology guidelines (2009) and the National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the willingness of health insurance companies and other payors to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of any healthcare reforms, including the Affordable Care Act, or changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success

other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

J.P. Fielder

Exact Sciences

(608) 210-5220

jpfielder@exactsciences.com

Jayme Maniatis or Jane Hauser

MSLGROUP

(781) 684-0770

exactsciences@mslgroup.com

To view the original version on PR Newswire, visit:

<http://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2016/Exact-Sciences-Cologuard-Wins-Prestigious-Prix-Galien-Award-for-Best-Medical-Technology-Product/default.aspx>

SOURCE EXACT SCIENCES CORP

[Click Here](#) for a complete listing of Exact Sciences Corporation press releases.

SUBSCRIBE TO THE BLOG

Email*

- ☐ Weekly
- ☐ Monthly

SUBSCRIBE

TOPICS

[Exact Sciences News\(108\)](#)

[Press Releases\(87\)](#)

[Company\(49\)](#)

[Investor Relations\(40\)](#)

[Colon Cancer News and Information\(20\)](#)

[Partnerships\(13\)](#)

[Healthy Living\(13\)](#)

[Hero of the Month\(10\)](#)

[Community\(5\)](#)

[Colon Cancer Awareness\(4\)](#)

[SEE ALL →](#)

MULTIMEDIA

VIDEOS

PHOTOS



© Exact Sciences Corporation
5505 Endeavor Lane
Madison, WI 53719
[Contact Us](#)

QUICK LINKS

About
Terms of Use
Purchasing Terms
Exact Sciences for Suppliers
Patents & Trademarks
Privacy Policy
HIPAA Notice
Coordinated Vulnerability
Disclosure
FCOI Policy
Do Not Sell My Info
[Cologuard.com](#)

FOLLOW US ON

